Product Information
TRIAMCINOLONE 0.147 MG/G SPRAY is a generic product labeled by Padagis Israel Pharmaceuticals Ltd, priced at $2.8300 per GM under NDC 45802004502. Its NADAC has been published 325 times since Apr 20, 2016.
FDA first approved this application on Apr 13, 2015. Its Orange Book therapeutic-equivalence code is AT.
Strength
.147 mg/g
Manufacturer
Padagis Israel Pharmaceuticals LtdNDC
45802004502
Classification
Generic
Dosage Form
AEROSOL, SPRAY
Route
TOPICAL
Effective Date
9/23/2026
Active Ingredients
TRIAMCINOLONE ACETONIDEApproval Type
Generic (ANDA)
FDA Application
ANDA205782FDA Approved
4/13/2015
TE Code
AT
On Market Since
4/17/2015
Pharmacological Classes
Price Statistics
The NADAC for TRIAMCINOLONE 0.147 MG/G SPRAY has been published 325 times since Apr 20, 2016, and over the history we have for it it has declined 8.3%. The table below summarizes its recorded NADAC range and movement.
| Current price | $2.8300 per GM |
|---|---|
| All-time high | $3.1748 (Jul 15, 2026) |
| All-time low | $1.6948 (Oct 23, 2024) |
| 52-week high | $3.1748 |
| 52-week low | $2.1461 |
| Median price | $2.8307 |
| Average price | $2.6934 |
| Largest weekly change | +56.2% (Feb 19, 2025) |
| Weeks tracked | 325 |
| Tracking since | Apr 20, 2016 |
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 32% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Padagis Israel Pharmaceuticals Ltd manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Triamcinolone Acetonide market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Corticosteroid class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of TRIAMCINOLONE 0.147 MG/G SPRAY?
The current National Average Drug Acquisition Cost (NADAC) for TRIAMCINOLONE 0.147 MG/G SPRAY, manufactured by Padagis Israel Pharmaceuticals Ltd, is $2.8300 per GM (NDC 45802004502), effective Sep 30, 2026.
How has the price of TRIAMCINOLONE 0.147 MG/G SPRAY changed over time?
Over the history we have for it, the NADAC for TRIAMCINOLONE 0.147 MG/G SPRAY has declined 8.3%. It has been tracked across 325 weekly CMS publications since Apr 20, 2016.
What are the highest and lowest recorded NADAC prices for TRIAMCINOLONE 0.147 MG/G SPRAY?
Since Apr 20, 2016, the NADAC for TRIAMCINOLONE 0.147 MG/G SPRAY has ranged from a low of $1.6948 (Oct 23, 2024) to a high of $3.1748 (Jul 15, 2026), with a median of $2.8307 per GM.
Are there cheaper alternatives to TRIAMCINOLONE 0.147 MG/G SPRAY?
Yes. 1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, TRIAMCINOLONE 0.147 MG/G SPRAY, is $1.9307 per GM — about 32% below TRIAMCINOLONE 0.147 MG/G SPRAY.
Who manufactures TRIAMCINOLONE 0.147 MG/G SPRAY?
TRIAMCINOLONE 0.147 MG/G SPRAY (NDC 45802004502) is labeled by Padagis Israel Pharmaceuticals Ltd, and CMS classifies it as a generic product.